Target intelligence / Profile preview

Coenzyme Q-cytochrome c reductase (Complex III) (Complex III)

Target
Complex III
Molecular classification
Enzyme, Oxidoreductase, Mitochondrial respiratory chain complex, Transmembrane protein
01

Overview

Coenzyme Q-cytochrome c reductase, also known as Complex III or the cytochrome bc1 complex, is a multi-subunit enzyme located in the inner mitochondrial membrane [1, 2]. It is a critical component of the mitochondrial electron transport chain, where it facilitates the transfer of electrons from ubiquinol to cytochrome c while simultaneously pumping protons into the intermembrane space to drive ATP synthesis [2, 3]. Beyond energy production, Complex III is a significant source of reactive oxygen species (ROS), making it a key player in cellular redox signaling and oxidative stress [1, 12]. Mutations in its subunits are linked to various mitochondrial disorders, such as exercise intolerance and encephalomyopathies, and its dysfunction is implicated in neurodegenerative diseases and cancer [1, 17]. Pharmacologically, it is the primary target of the antimalarial drug atovaquone, which inhibits the enzyme's Qo site in parasites, and it is also a site of action for various research inhibitors and mitochondrial-targeted antioxidants [2, 9, 14].

Other names
Complex IIICytochrome bc1 complexUbiquinol-cytochrome c reductaseUbiquinone-cytochrome c oxidoreductaseMitochondrial respiratory chain complex IIICIIIUbiquinol:ferricytochrome-c oxidoreductase
02

Mechanism of action

Inhibition of electron transfer at the Qo or Qi binding sites of the cytochrome bc1 complex, leading to the collapse of the mitochondrial membrane potential and inhibition of ATP synthesis, or the restoration of electron transport chain function through substrate supplementation [1, 2, 10].

03

Biological functions

Electron transport chainOxidative phosphorylationATP synthesisProton pumpingReactive oxygen species generationCellular respiration
04

Disease associations

Mitochondrial diseaseCancerNeurodegenerative diseaseCardiovascular diseaseInfection
05

Safety considerations

Mitochondrial toxicityLactic acidosisIncreased oxidative stressDisruption of cellular energy metabolismPotential for drug-induced myopathy
06

Interacting drugs

Atovaquone

7 more in the full profile.

07

Biomarkers

Complex III activity levelsReactive oxygen species (ROS) levelsATP production rateLactate-to-pyruvate ratioCoenzyme Q10 plasma levels

Beyond the preview

Go deeper on Coenzyme Q-cytochrome c reductase (Complex III) (Complex III).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coenzyme Q-cytochrome c reductase (Complex III) (Complex III).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call